Amir Najafi, MD
Interventional Cardiology · Bel Air, MDNPI 1790952372
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 67.1% of it on its own, with 48 other manufacturers making up the rest. 2025 is the largest year on record at $61,202, more than ten times the $2,984 reported in 2019. Among interventional cardiology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 836 payments — averaging $97.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$55K
- Edwards Lifesciences$10K
- Abbott$2K
- Medtronic$2K
- Kestra Medical Technology Services, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $11K from 43 others
What the payments were for
- Consulting fees$8,45010%
- Speaking & faculty fees$47,54658%
- Travel & lodging$5,7597%
- Food & beverage$19,73224%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$54,146
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$5,449
- SAPIEN 3 Ultra RESILIA$2,702
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,416
- Assure WCD$609
- 3F$233
- CoreValve Evolut$175
- XIENCE SIERRA$144
- LINQ II$136
- COBALT DR MRI SURESCAN$135
- ONYX FRONTIER$128
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- Ozempic$122
- COREVALVE EVOLUT R$114
- Watchman$113
- DRAGONFLY OPSTAR$104
- AMPLATZER AMULET$103
- OPTIS$103
- FlowTriever$103
How this compares
$81,610 in reported general payments places this provider in the 90th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 382 | $511,728 |
| XareltoRivaroxaban | 179 | $261,686 |
| EntrestoSacubitril/Valsartan | 104 | $155,574 |
| Repatha SureclickEvolocumab | 33 | $33,995 |
| JardianceEmpagliflozin | 17 | $27,494 |
| BrilintaTicagrelor | 37 | $25,840 |
| FarxigaDapagliflozin Propanediol | 13 | $15,813 |
| Ranolazine ErRanolazine | 65 | $10,961 |
| Metoprolol Succinate | 491 | $9,277 |
| VascepaIcosapent Ethyl | 12 | $8,025 |
| Atorvastatin Calcium | 475 | $5,997 |
| Rosuvastatin Calcium | 237 | $5,994 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $4,906 |
| Candesartan Cilexetil | 43 | $4,227 |
| Ezetimibe | 101 | $4,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $715 | $511,728382 claims |
| Johnson & JohnsonXarelto | $1,096 | $261,686179 claims |
| NovartisEntresto | $776 | $155,574104 claims |
| AstraZenecaBrilinta, Farxiga | $517 | $41,65250 claims |
| Boehringer IngelheimJardiance | $633 | $27,49417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Bel Air
- Ali TabrizchiBel Air$66K
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Homam IbrahimSilver Spring$49K
- Jon ResarBaltimore$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.